Physician profile
Jacob Abraham
NPI 1528588142
$4,040.23
in general payments reported to CMS, 2019-2025
27 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $221 · 2021: $302 · 2022: $389 · 2023: $631 · 2024: $1,982 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676 · Consulting Fee: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.48 |
| Consulting Fee | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,250.00 | 2024 | Cardiomems |
| Amgen INC. | $429.97 | 2019-2025 | Repatha, Evenity, Krystexxa |
| Janssen Pharmaceuticals, INC | $330.03 | 2022-2024 | Xarelto |
| Glaxosmithkline, LLC. | $313.58 | 2020-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $302.28 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $281.84 | 2020-2024 | Lokelma, Farxiga, Airsupra |
| Lilly USA, LLC | $188.33 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $182.70 | 2021-2025 | Linzess, Viberzi, Vraylar |
| Axsome Therapeutics, INC. | $146.32 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $74.39 | 2020 | |
| Corcept Therapeutics | $64.74 | 2025 | Korlym |
| Abiomed | $45.30 | 2025 | |
| Esperion Therapeutics, INC. | $44.79 | 2021-2023 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $43.62 | 2025 | Dupixent |
| Exact Sciences Corporation | $39.34 | 2023 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.98 | 2023 | Jardiance, Synjardy |
| Ucb, INC. | $38.85 | 2023-2024 | Nayzilam |
| Bayer Healthcare Pharmaceuticals INC. | $35.83 | 2024-2025 | |
| Dexcom, INC. | $30.64 | 2022 | |
| Ironwood Pharmaceuticals, INC | $29.90 | 2022 | |
| Pfizer INC. | $25.17 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.50 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.98 | 2024 | Voquezna |
| Horizon Therapeutics Plc | $19.21 | 2023 | Krystexxa |
| Astellas Pharma US INC | $17.28 | 2023 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $13.36 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.